

Cadila Pharma unveils Obeticholic acid tablets in India

07 September 2020 | News

For the treatment of PBC, currently, Ursodeoxycholic acid (UDCA) is being extensively used



Ahmedabad based Cadila Pharmaceuticals has launched Obetocad in India, a generic version of Ocaliva® (Obeticholic Acid) primarily used for the treatment of Primary Biliary Cholangitis (PBC).

For the treatment of PBC, currently, Ursodeoxycholic acid (UDCA) is being extensively used. Around 40% of the patients do not respond to UDCA treatment and 5-10% of patients observe severe side effects. Obetocad can be used as a monotherapy or along with UDCA for the treatment of patients who are unresponsive to UDCA therapy.

Obetocad is available in 5 mg and 10 mg tablets in packs of 10 tablets. It is also USFDA and EMA approved and recently received its DCGI approvals. Obetocad also has the potential to be used in other indications such as NASH, NAFLD, severe acute hepatitis, bile acid diarrhea, bariatric and gallstone diseases.

Cadila Pharmaceuticals has always been focused on making sure high quality, affordable, and life-saving treatments are within the reach of patients. Cadila Pharma has also recently launched 4 biosimilar products in the past 2 months under the brand name BevaroTM, RitucadTM, CadalimabTM, and NuPTH for the treatment of cancer and osteoporosis. Cadila plans to launch multiple biosimilar products this year for the Indian Market.

Cadila, one of the largest privately-held pharmaceutical companies in India, has recently concluded and cleared USFDA inspection successfully in February 2020. Over the past six decades, Cadila Pharmaceuticals has been engaged in the development and manufacturing of affordable medicines and in making them available for patients across the world. Its innovation-driven drug discovery processes ensure the health and well-being of people around the world.